Teva Pharmaceuticals USA, Inc. received FDA approval on May 3, 2012, for its ANDA 091347, enhancing competition in the sildenafil-alternative market following the patent cliff for Pfizer's breakthrough ED medication. The launch of generic vardenafil hydrochloride is anticipated to stimulate price competition and increase market accessibility in the erectile dysfunction sector.